Stock EFTR EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
2.05 USD -3.76% Intraday chart for eFFECTOR Therapeutics, Inc. -8.89% -82.46%
04-04 Health Care Down on Retreat From Risk -- Health Care Roundup DJ
04-04 Top Midday Decliners MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
AQ
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
GL
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
AQ
EFFECTOR Therapeutics Announces Reverse Stock Split
GL
EFFECTOR Therapeutics Announces Reverse Stock Split
AQ
EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA FROM DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN ER+ METASTATIC BREAST CANCER PATIENTS
AQ
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
GL
EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
AQ
EFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
GL
The role of STRIs in cancer
AQ
EFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
GL
EFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GL
EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
GL
EFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
AQ
EFFECTOR THERAPEUTICS TO COLLABORATE WITH THE NORTHWESTERN UNIVERSITY DIVISION OF HEMATOLOGY AND ONCOLOGY ON AN INVESTIGATOR-INITIATED PHASE 1 DOSE ESCALATION TRIAL
AQ
EFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
GL
EFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
AQ
EFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. News eFFECTOR Therapeutics, Inc.
  5. Press Releases